首页/跨境头条/官司
关注美国官司2026/08/21 20:00来源:jhenderson2

FTC Files Amicus Brief to Protect Competition in Biologic Drug Markets

The Federal Trade Commission filed an amicus brief in an antitrust case alleging that drug manufacturer Amgen illegally acquired exclusive rights to patent applications that it shaped to cover Enbrel—a drug used to treat rheumatoid arthritis and other inflammatory conditions—allo

SOURCE CONTENT

来源摘要(中文)

以下内容按来源提供的信息直接整理,保留原有事实与表达顺序。

The Federal Trade Commission filed an amicus brief in an antitrust case alleging that drug manufacturer Amgen illegally acquired exclusive rights to patent applications that it shaped to cover Enbrel—a drug used to treat rheumatoid arthritis and other inflammatory conditions—allowing Amgen to extend its monopoly over the biologic drug. View Press Release

内容边界来源仅提供摘要时,本站只展示该摘要,不自行补写成完整报道;详细条款及后续修订以文末原始链接为准。

BUSINESS NOTE

经营分析

涉及法律或知识产权风险,选品与投放前应复核权利状态。 建议先区分起诉、禁令、判决或和解阶段,再比对涉案商标、专利、图片与自身商品;涉及正式投诉或资金冻结时,应尽快交由目标市场专业人员处理。

SOURCES

原始信息来源

查看原始页面可核对标题、正文、发布日期、适用范围与后续修订。

  1. 官方jhenderson2
    来源发布日期:2026/08/21 20:00查看原始来源 ↗
英文内容由系统自动翻译为中文,仅调整语言,不扩写来源事实;若译文与原页面存在差异,以原始来源为准。